Monday, August 29, 2016

BRIEF-Nymox says new phase 3 long-term U.S.results for fexapotide show major decrease in prostate cancer

… . results for prostate
enlargement drug fexapotide show decrease in prostate cancer
* Fexapotide has … major reduction in
incidence of prostate cancer versus placebo
* Expects to file …

No comments:

Post a Comment